We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jeffrey Berns

Jeffrey S Berns MD, FACP, FASN

Professor of Medicine, Perelman School of Medicine, University of Pennsylvania; Associate Chief, Renal, Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia

Jeffrey S. Berns, MD

Dr. Jeffrey Berns is Professor of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. After 12 years in private practice, Dr. Berns joined the faculty of the University of Pennsylvania, where he is Associate Chief of the Renal, Electrolyte, and Hypertension Division, Director of the Nephrology Fellowship Training Program, and Associate Dean for Graduate Medical Education.

Dr. Berns is co-deputy editor of the American Journal of Kidney Diseases (AJKD) and Nephrology Editor-in-Chief and Dialysis Section co-editor for UpToDate. He is Chair of the American Board of Internal Medicine (ABIM) Nephrology Subspecialty Board. He is immediate Past-President of the National Kidney Foundation. 

Dr. Berns has authored over 200 articles and book chapters. He has been actively involved in medical education throughout his career and is the recipient of numerous teaching awards from the University of Pennsylvania. Dr. Berns maintains a general nephrology practice at the Hospital of the University of Pennsylvania.

Disclosures

Dr. Berns reports the following cnflict, he is on the Executive Committee of a now-completed study of a HIF Prolyl-hydroxylase inhibitor (Bayer) and of a now completed study of darbepoetin (Amgen).